Financial PerformanceThe company's EPS for the first quarter exceeded expectations, driven by a higher gross margin and lower R&D expenses.
Pipeline DevelopmentHarmony's late-stage pipeline remains on the cusp of multiple high-impact catalysts, including Phase 3 data in Fragile X syndrome, registrational studies in rare epilepsies, and the advancement of next-generation pitolisant formulations.
Revenue GrowthHarmony is off to a strong start in 2025, reporting 1Q25 net product revenue of $184.7M, up 20% year-over-year, driven by continued commercial execution in narcolepsy.